Literature DB >> 7980627

Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.

D D Ross1, D P Cuddy.   

Abstract

The ability of pH-step alkaline elution to isolate different size species of nascent DNA (nDNA) from intact cells was utilized to study the effects of 2',2'-difluorodeoxycytidine (dFdC) on DNA replication in HL-60 cells. Preincubation with dFdC caused a concentration-dependent decrease in overall [3H]thymidine incorporation into DNA, accompanied by an increase in the proportion of radiolabel accumulated in small nDNA fragments. Twenty-four hours following removal of dFdC, radiolabel progressed from smaller to larger fragments and into genomic-length DNA. At initial concentrations of exposures to dFdC or cytosine arabinoside (ara-C) that caused 50% lethality (LC50) to HL-60 cells (40 and 50 nM, respectively), slower and less complete transit of nDNA from small subreplicon-length fragments through larger intermediates to genomic-length DNA was observed for nDNA fragments containing incorporated [3H]dFdC than for fragments containing [3H]ara-C. This was accomplished with less [3H]dFdC incorporated into DNA than [3H]ara-C at these extracellular concentrations of drug. Pulse-chase studies, using higher concentrations of radiolabeled drug, similarly revealed that nDNA fragments containing incorporated dFdC, like those containing ara-C, progressed with respect to time into larger nDNA intermediates and ultimately into genomic-length DNA; however, such progression for nDNA fragments containing dFdC was less complete than for fragments containing ara-C. The radioactivity incorporated into DNA represented authentic dFdC, as determined by DNA degradation studies, and was stable in DNA for at least 48 hr after removal of extracellular [3H]dFdC. Some of the effects of dFdC on ribonucleotide reduction in HL-60 cells were assessed by measurement of the intracellular pools of dCTP and dGTP. The drug had a greater effect on pools of dGTP than of dCTP, with transient reductions in dGTP observed at concentrations that encompass the LC50 for dFdC. These studies suggest that the interaction with DNA synthesis is an important component of the cytotoxicity of dFdC in HL-60 cells. Because it is incorporated progressively through nDNA compartments and ultimately into genomic-length DNA, dFdC should be categorized as an agent that slows DNA elongation in the intact cell, and not as a chain terminator in the absolute sense.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7980627     DOI: 10.1016/0006-2952(94)90207-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Miyake; Takashi Higuchi; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Shree Ram Singh; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

2.  Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.

Authors:  Sisi Wang; Hongyong Zhang; Liang Cheng; Christopher Evans; Chong-Xian Pan
Journal:  Anticancer Res       Date:  2010-11       Impact factor: 2.480

Review 3.  Gemcitabine and radiosensitization in human tumor cells.

Authors:  D S Shewach; T S Lawrence
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity.

Authors:  Jessica J O'Konek; Brendon Ladd; Sheryl A Flanagan; Mike M Im; Paul D Boucher; Tico S Thepsourinthone; John A Secrist; Donna S Shewach
Journal:  Mutat Res       Date:  2010-01-08       Impact factor: 2.433

5.  Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

Authors:  Andries M Bergman; Auke D Adema; Jan Balzarini; Skjalg Bruheim; Iduna Fichtner; Paul Noordhuis; Oystein Fodstad; Finn Myhren; Marit L Sandvold; Hans R Hendriks; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2010-01-12       Impact factor: 3.850

6.  Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.

Authors:  Johan Vande Voorde; Suna Sabuncuoğlu; Sam Noppen; Anders Hofer; Farahnaz Ranjbarian; Steffen Fieuws; Jan Balzarini; Sandra Liekens
Journal:  J Biol Chem       Date:  2014-03-25       Impact factor: 5.157

7.  Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.

Authors:  Ha-Young Lee; Sang Joon Shin; Hyo Song Kim; Soo Jung Hong; Jung Woo Han; Seung Taek Lim; Jae Kyung Roh; Sun Young Rha
Journal:  Cancer Res Treat       Date:  2012-03-31       Impact factor: 4.679

8.  Antimetabolite Treatment for Pancreatic Cancer.

Authors:  Malyn May Asuncion Valenzuela; Jonathan W Neidigh; Nathan R Wall
Journal:  Chemotherapy (Los Angel)       Date:  2014-12

9.  Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.

Authors:  Clayton S Lewis; Christina Voelkel-Johnson; Charles D Smith
Journal:  Oncotarget       Date:  2016-09-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.